Tag Archives: Johnson & Johnson

After Getting ‘Stealth Bailout’ During Pandemic, US Corporations Try to Kill Proposed Tax Hikes

Leave a reply

“When it’s time to finally put workers first, big businesses are spending millions to maintain their advantage and preserve the status quo,” said Kyle Herrig of Accountable.US.

By Jessica Corbett, staff writer for Common Dreams.  Published 10-21-2021

Members of the Patriotic Millionaires hold a federal tax filing day protest in New York City. Photo: Michael Kink/Twitter

Major U.S. companies that got a “stealth bailout” thanks to congressional pandemic relief legislation are now lobbying against President Joe Biden’s proposal to hike taxes on wealthy individuals and corporations through the Build Back Better package, according to a new Accountable.US analysis provided exclusively to Common Dreams.

Accountable.US takes aim at the recent lobbying activities—and in some cases, statements from top executives—of Apple, Baxter International, Bristol-Myers-Squibb, DuPont de Nemours, FedEx, Johnson & Johnson, Oracle, Walgreens Boots Alliance, and Walmart. Continue reading →

Share Button

‘Let’s Do Insulin Next,’ Says Ocasio-Cortez After Biden Backs IP Waiver to Boost Covid-19 Vaccine Access

Leave a reply

“We can do it with all lifesaving pharmaceuticals,” tweeted one group.

By Jessica Corbett, staff writer for Common Dreams. Published 5-5-2021

After the Biden administration on Wednesday caved to global pressure and endorsed waiving intellectual property protections for Covid-19 vaccines, progressives across the United States called for taking a similar approach to other lifesaving drugs and treatments made less accessible by Big Pharma’s greed.

“Let’s do insulin next,” tweeted Rep. Alexandria Ocasio-Cortez (D-N.Y.), a self-described “unapologetic advocate of Medicare for All” who also “believes that all people must have access to safe and affordable prescription medications.” Continue reading →

Share Button

Pressure Campaign Kicks Off in US to Force Big Pharma and Biden to End Vaccine Apartheid

Leave a reply

The absence of a WTO patent waiver, say public health advocates, “means we won’t end the pandemic, millions of people will die, and the global economy will suffer.”

By Kenny Stancil, staff writer for Common Dreams. Published 4-22-2021

“Pfizer has spent the past year making billions of dollars in profits while people continue to die from Covid-19,” tweeted Health GAP on April 22, 2021. “It’s time to #FreeTheVaccine so the whole world has access to these life-saving vaccines!” (Photo: Twitter screengrab via Health GAP)

As vast global inequalities in access to Covid-19 vaccines exacerbate the ongoing pandemic, a coalition of progressive groups in the U.S. kicked off a week of action Thursday to urge President Joe Biden to support a temporary suspension of patent protections and to pressure pharmaceutical corporations to share technology in order to maximize the worldwide production of life-saving doses.

In the coming days, public health campaigners will gather at the headquarters of Pfizer, Moderna, and Johnson & Johnson in an attempt to push the major drugmakers to share relevant technology through the World Health Organization’s Covid-19 Technology Access Pool. Continue reading →

Share Button

Big Pharma Quietly Planning Price Hike for Covid Vaccines in ‘Near Future’: Report

Leave a reply

“As this shifts from pandemic to endemic, we think there’s an opportunity here for us,” said Pfizer’s Chief Financial Officer Frank D’Amelio.

By Kenny Stancil, staff writer for Common Dreams. Published 3-19-2021

Photo: KALW/CC

Eager to capitalize on the lasting presence of the coronavirus, executives at Johnson & Johnson, Moderna, and Pfizer—the pharmaceutical corporations that supplied the Covid-19 vaccines approved for use in the U.S.—are quietly planning to hike prices on doses “in the near future,” once they decide the pandemic is over, The Intercept’s Lee Fang reported Thursday.

Although the rapid development of coronavirus vaccines—made possible by large infusions of public resources—has given Big Pharma companies “a boost in goodwill… the public is still sensitive to drug pricing and the reputational risk has, so far, curtailed their ability to reap large financial rewards,” Fang noted. “But that environment, they hope, will change once the pandemic ends: a date that drugmakers themselves reserve the right to declare.” Continue reading →

Share Button